Results 81 to 90 of about 6,839 (229)

Genomic and proteomic insights into hidradenitis suppurativa

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
A dual pathogenic model of HS involving both epithelial dysfunction and systemic inflammation is supported. The HLA‐DRA association hints at autoimmune overlap, but the proteomic signature which is dominated by innate immune mediators favours an autoinflammatory classification, which may guide future therapeutic strategies and patient stratification ...
Maria Argyropoulou   +8 more
wiley   +1 more source

THE TREATMENT OF ACNE SCARS

open access: yes, 2009
Acne scars represent a real challenge to the dermatologist: several histological and macroscopical distinctive features require different therapeutic approaches. Among the several available classification, Goodman et al.
FABBROCINI, GABRIELLA
core  

Updated Management of Atrophic Post Acne Scars: Review Article

open access: yes, 2022
Background: Hair follicle and sebaceous gland inflammation causes acne, which is a long-term, chronic skin condition. The androgen-induced sebum overproduction leads to first acne appearance.
AlBalat, Waleed Mohammed   +2 more
core  

Darier disease—A review highlighting new insights from the Darier Disease International Task Force

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This review provides a global, clinically focused overview of DD, detailing cutaneous and extracutaneous manifestations, disease classification and severity scoring. It emphasizes early recognition, multidisciplinary management and practical guidance for dermatologists to apply evidence‐based care in diverse skin phototypes. Abstract Darier disease (DD)
Sofia Labbouz   +49 more
wiley   +1 more source

Efficacy of Heterologous Type I Collagen Injections in Treating Atrophic Acne Scars: A Prospective Study. [PDF]

open access: yesSkin Appendage Disord
Introduction: Treatment of acne scars includes laser therapies, microneedling, chemical peels, and dermal fillers. Herein, we sought to assess the efficacy and safety of heterologous type I collagen injections (HT1Cs) on atrophic acne scars. Methods: One
Gkouvi A   +4 more
europepmc   +2 more sources

It looks like acne, but...

open access: yes, 2012
Acne is one of the commonest skin diseases that dermatologists have to treat. The diagnosis of acne is usually made from the finding of the following aspects: 1) clinical features: acne vulgaris is characterized by a mixture of non-inflamed (open and ...
Bettoli V   +7 more
core  

Ablative Fractional CO2 Laser for Facial Atrophic Acne Scars

open access: yes, 2018
Ablative fractional carbon dioxide laser resurfacing is a well-established treatment for acne scars. However, there are limited consensus and guidelines regarding the procedure, such as its treatment plan, efficacy, and safety.
Yaqin Xu, Yunhua Deng
core   +1 more source

Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In this randomized controlled trial, cumulative isotretinoin doses of 120 and 150 mg/kg showed similar relapse rates at 12 months. Both regimens achieved substantial and comparable reductions in inflammatory acne lesions across the face, chest and back.
Ruggero Cascio Ingurgio   +16 more
wiley   +1 more source

Evaluation of the efficacy of microneedle fractional radiofrequency in Turkish patients with atrophic facial acne scars

open access: yes, 2019
Background: Scarring is an undesirable and severe complication of acne resulting in loss of self-esteem in young people. Although microneedle fractional radiofrequency (MFR) system has emerged as a good option to treat acne scars in recent years, it was ...
Belli, Aslı Akın
core   +2 more sources

Thirty Years of Autologous Platelet Concentrates: From Platelet‐Rich Plasma to Platelet‐Rich Fibrin

open access: yesJournal of Periodontal Research, EarlyView.
This review highlights the 30 years of evolution of APCs, with a focus on their clinical applications and recent technological advancements. ABSTRACT Nearly three decades have now passed since autologous platelet concentrates (APCs) were introduced into clinical practice.
Richard J. Miron   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy